Laser treatment for low- and intermediate risk prostate cancer
Transperineal Laser Ablation for Low and Intermediate Risk Prostate Cancer: a Single Cohort Analysis
This study is testing a new laser treatment for men with low- and intermediate risk prostate cancer to see how well it works and how it affects their quality of life after the procedure.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | Male |
| Sponsor | San Carlo di Nancy Hospital Academic / other |
| Locations | 1 site (Roma, RM) |
| Trial ID | NCT05584787 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Echolaser transperineal focal therapy in treating patients with low- and intermediate risk prostate cancer. It aims to assess short and intermediate term oncological outcomes, as well as functional outcomes and quality of life post-treatment. Participants will undergo multiparametric prostate MRI at 3 and 12 months for oncological monitoring, and a re-fusion biopsy will be performed after 12 months. Functional outcomes and quality of life will be evaluated at 3, 6, and 12 months following the procedure.
Who should consider this trial
Good fit: Ideal candidates are men diagnosed with low- and intermediate risk prostate cancer classified as ISUP 1-2.
Not a fit: Patients with urothelial cancer, contraindications for MRI, or multifocal prostate cancer may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could provide a less invasive option for managing low- and intermediate risk prostate cancer while preserving quality of life.
How similar studies have performed: Other studies have shown promising results with laser ablation techniques for prostate cancer, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with low- and intermediate risk prostate cancer classified as International Society for Urological Pathology, ISUP 1-2. Exclusion Criteria: * patients diagnosed with urothelial cancer * contraindications for MRI * Multifocal prostate cancer
Where this trial is running
Roma, RM
- San Carlo di Nancy Hospital — Roma, Rm, Italy (Recruiting)
Study contacts
- Principal investigator: Pierluigi Bove, MD — San Carlo di Nancy Hospital
- Study coordinator: Valerio Iacovelli, MD, PhD
- Email: valerio.iacovelli85@gmail.com
- Phone: +393398461654
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.